STAG2 and myelodysplastic syndrome: At the same time, patients with MDS-f exhibited lower incidences of TET2 (0% vs. 19%, P = 0.020) and STAG2 mutations (8% vs. 27%, P = 0.050) compared to those diagnosed with MDS-IB.